Aireen is an AI software medical device company focusing on diagnosing chronic diseases from retinal images. The focus is to provide non-invasive, pain-less screening of chronic diseases by analyzing digital images of the retina.

The retina is the only place in the human body where blood vessels can be seen by the naked eye. Artificial intelligence is cutting-edge breakthrough technology which allows for the precise identification of changes to the retina and their relation with number of chronic diseases.

• Since May 2023 Aireen DR diabetic retinopathy detection has been certified as class IIb EU-MDR medical device.

• In May 2024 age related macular degeneration detection was certified as class IIb EU-MDR medical device.

• In May 2025 Aireen was certified to comply with ISO 27001 standard for information security management.

Our current development activities are aimed at cardiovascular and neurodegenerative disease detection, again from retinal images.